Novartis Q3 Results and Pipeline Progress
Novartis, an innovative medicines company, delivers solid sales and core operating income growth with strong pipeline progress in Q3 and reaffirms FY 2025 guidance.
Novartis aims to reimagine medicine to improve and extend people's lives, empowering patients, healthcare professionals, and societies in the face of serious disease, with its medicines reaching 296 million people worldwide.
Resources and Commitments
- Information for patients and caregivers: clinical trial recruiting, managed access programs, funding opportunities, and side effects reporting.
- Resources for healthcare professionals: clinical trial recruiting, grant funding, congresses, and country-level information.
- Environmental, social, and governance commitments: providing access to innovative medicines, protecting the environment, and upholding high ethical standards.
Discover how Novartis turns breakthrough science into transformative, high-value treatments.
Learn about Novartis' positive impact on the world through the Novartis in Society Integrated Report.
Author's summary: Novartis delivers solid Q3 results.
More News
- Hemab closes $157m in funding for bleeding disorder treatments
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Industrial profits post fast growth-Dahe.cn - The first brand of local news website in Henan.
- Schenectady launches school zone camera demonstration program
- Cisco and G42 Deepen US-UAE Technology Partnership to Build Secure, End-to-End AI Infrastructure in the UAE
- Quantum Threats Demand Post-Quantum Cryptography Now
- Suspect in Charlie Kirk killing can wear street clothes in court amid ‘extraordinary’ attention | Fulton Sun
- Most of the world’s space launches are controlled by just three countries
- An NYPD Camera Points Directly Into Their Bedroom. They’re Suing the City Over It.
- Liverpool decline Slot press conference before Palace cup tie